Potent pseudosubstrate-based peptide inhibitors for p60(c-src) protein tyrosine kinase

Cancer Research

Volumn 57, Issue 10, 1997, Pages 1877-1881

  Lou, Qiang ^a   Leftwich, Margaret E ^a   McKay, R Trent ^a   Salmon, Sydney E ^a   Rychetsky, Lenka ^a   Lam, Kit S ^a,b  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN INHIBITOR; PROTEIN KINASE P60; SYNTHETIC PEPTIDE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; DRUG POTENCY; DRUG SPECIFICITY; DRUG SYNTHESIS; DRUG TARGETING; ENZYME ACTIVE SITE; ENZYME PHOSPHORYLATION; ENZYME SUBSTRATE; HUMAN; PEPTIDE SYNTHESIS; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; ENZYME INHIBITORS; HUMANS; KINETICS; MOLECULAR SEQUENCE DATA; OLIGOPEPTIDES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS PP60(C-SRC); SUBSTRATE SPECIFICITY; TEMPLATES, GENETIC;

EID: 0030963144     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Tsygankow, A., and Bolen, J. The Src family of tyrosine protein kinases in hemopoietic signal transduction. Stem Cells, 11: 371-380, 1993.
2. Wilkis, A. F. Protein tyrosine kinase growth factor receptors and their ligands in development, and differentiation, and cancer. Adv. Cancer Res., 60: 43-73, 1993.
3. Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., and McGuire, W. L. Human breast cancer. Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (Washington DC), 235: 177-182, 1987.
4. Konopka, J. B., Watanabe, S., and Witte, O. N. An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity. Cell, 37: 1035-1042, 1984.
5. Clark, S. S., Mclaughlin, J., Timmons, M., Pendergast, A. M., Ben-Neriah, Y., Dow, L. W., Crist, W., Rovera, G., Smith, S. D., and Witte, O. N. Expression of a distinctive BCR-ABL oncogene in Ph1-positive acute lymphocytic leukemia (ALL). Science (Washington DC), 239: 775-777, 1988.
6. Ozanne, B., Richard, C. S., Hendler, F., Burns, D., and Gusterson, B. Over-expression of the EGF receptor is a hallmark of squamous cell carcinoma. J. Pathol., 149: 9-14, 1986.
7. c-src protein kinase activity in human colon carcinoma. Proc. Natl. Acad. Sci. USA, 84: 2251-2225, 1987.
8. c-src with two major signaling pathways in human breast cancer. Proc. Natl. Acad. Sci. USA, 91: 83-87, 1994.
9. c-src in low grade human bladder carcinoma. Cancer Res., 52: 1457-1992, 1992.
10. Levitzki, A., and Gazit, A. Tyrosine kinase inhibition: an approach to drug development. Science (Washington DC), 267: 1782-1787, 1995.
11. Fry, D. W. Recent advances in tyrosine kinase inhibitors. Annu. Rep. Med. Chem., 31: 151-160, 1996.
12. Chang, C., and Geahlen, R. L. Protein-tyrosine kinase inhibition: mechanism-based discovery of anti-tumor agents. J. Natl. Prod., 55: 1529-1590, 1992.
13. Burke, T. R., Jr. Protein-tyrosine kinase: potential targets for anticancer drug development. Stem Cells, 12: 1-6, 1994.
14. Fry, D. W., Kraker, A. J., McMichael, A., Ambroso, L. A., Nelson, J. M., Leopold, W, R., Connors, R. W., and Bridges, A. J. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science (Washington DC), 265: 1093-1095, 1994.
15. Dow, R. L., Chou, T. T., Bechle, B. M., Goddard, C., and Larson, E. R. Identification of tricyic analogs related to ellagic acid as potent/selective tyrosine protein kinase inhibitors. J. Med. Chem., 37: 2224-2231, 1994.
16. Dolle, R. E., Dunn, J. A., Bobko, M., Singh, B., Kuster, J. E., Baizman, E., Harris, A. L., Sawutz, D. G., Miller, D., Wang, S., Faltynek, C. R., Xie, W., Sarup, J., Bode, D. C., Pagani, E. D., and Silver, P. J. 5,7-Dimethoxy-3-(4-pyridinyl)quinoline is a potent and selective inhibitor of human vascular β-type platelet-derived growth factor receptor tyrosine kinase. J. Med. Chem., 37: 2627-2629, 1994.
17. Buchdunger, E., Trinks, U., Mett, H., Regenass, U., Muller, M., Meyer, T., McGlynn, E., Pinna, L. A., Traxler, P., and Lydon, N. B. 4,5-Dianilinophthalimide: a protein-tyrosine kinase inhibitor with selectivity for the epidermal growth factor receptor signal transduction pathway and potent in vivo antitumor activity. Proc. Natl. Acad. Sci. USA, 91: 2334-2338, 1994.
18. Maguire, M. P., Sheets, K. R., McVety, K., Spada, A. P., and Zilberstein, A. A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J. Med. Chem., 37: 2129-2137, 1994.
19. Trinks, U., Buchdunger, E., Furet, P., Kump, W., Mett, H., Meyer, T., Muller, M., Regenass, U., Rihs, G., Lydon, N., and Traxler, P. Dianilinophthalimides. Potent and selective, ATP-competitive inhibitors of the EGF-receptor protein tyrosine kinase. J. Med. Chem., 37: 1015-1027, 1994.
20. Thompson, A. M., Bridges, A. J., Fry, D. W., Kraker, A. J., and Denny, W. A. Tyrosine kinase inhibitors. 7. 7-Amino-4-(phenylamino)- and 7-amino-4-[(phenylmethyl)amino]pyrido[4,3-d]pyrimidines: a new class of inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor. J. Med. Chem., 38: 3780-3788, 1995.
21. Buchdunger, E., Zimmermann, J., Mett, H., Meyer, T., Muller, M., Regenass, R., and Lydon, N. B. Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class. Proc. Natl. Acad. Sci. USA, 92: 2558-2562, 1995.
22. Rewcastle, G. W., Denny, W. A., Bridges, A. J., Zhou, H., Cody, D. R., McMichael, A., and Fry, D. W. Tyrosine kinase inhibitors. 5. Synthesis and structure-activity relationships for 4-[(phenylmethyl)amino]- and 4-(phenylamino)quinazolines as potent adenosine 5′-triphosphate binding site inhibitors of the tyrosine kinase domain of the epidermal growth factor receptor. J. Med. Chem., 38: 3482-3487, 1995.
23. Hanke, J. H., Gardner, J. P., Dow, R. L., Changelian, P. S., Brissette, W. H., Weringer, E. J., Pollok, B. A., and Connelly, P. A. Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. J. Biol. Chem., 271: 695-701, 1996.
24. Brown, M. T., and Cooper, J. A. Regulation, substrates and functions of Src. Biochim. Biophys. Acta, 1287: 121-149, 1996.
25. Lam, K. S., Wu, J. Z., and Lou, Q. Identification and characterization of a novel synthetic peptide substrate specific for Src-family protein tyrosine kinases. Int. J. Pept. Protein Res., 45: 587-592, 1995.
26. Songyang, Z., Carraway, K. L., III, Eck, M. J., Harrison, S. C., Feldman, R. A., Mohammadi, M., Schlessinger, J., Hubbard, S. R., Smith, D. P., Eng, C., Lorenzo, M. J., Ponder, B. A. J., Mayer, B. J., and Cantley, L. C. Catalytic specificity of protein-tyrosine kinases is critical for selective signalling. Nature (Lond.), 373: 536-539, 1995.
27. Lam, K. S., Salmon, S. E., Hersh, E. M., Hruby, V. J., Kazmierski, W. M., and Knapp, R. J. A new type of synthetic peptide library for identifying ligand-binding activity. Nature (Lond.), 345: 82-84, 1991.
28. Wu, J. Z., Ma, Q. N., and Lam, K. S. Identifying substrate motifs of protein kinases by a random library approach. Biochemistry, 33: 14825-14833, 1994.
29. c-src protein tyrosine kinase. Lett. Pept. Sci., 2: 289-296, 1996.
30. c-src protein tyrosine kinase. Bioorg. Med. Chem., 4: 677-682, 1996.
31. Kemp, B. E., and Pearson, R. B., and House, C. M. Pseudosubstrate-based peptide inhibitors. Methods Enzymol., 200: 287-316, 1991.
32. Stewart, J. M., and Young, J. D. Solid Phase Peptide Synthesis. Rockford, IL: Pierce Chemical Company, 1984.
33. Atherton, E., and Sheppard, R. C. Solid Phase Peptide Synthesis. Oxford, United Kingdom: IRL Press, 1989.
34. Lou, Q., Wu, J. Z., and Lam, K. S. A protein kinase assay system for both acidic and basic peptides. Anal. Biochem., 235: 107-109, 1996.
35. Hardie, G., and Hanks, S. The protein kinase: protein-tyrosine kinases. Facts Book, pp. 7-47. San Diego, CA: Academic Press, 1996.
36. Wu, J. Z., Phan, H., Salmon S. E., and Lam, K. S. Development of a selective pseudosubstrate-based peptide inhibitor of p60c-src protein tyrosine kinase. Lett. Pept. Sci., 3: 309-316, 1996.
37. Cheng, H. C., Matsuura, I., and Wang, J. H. In vitro substrate specificity of protein tyrosine kinases. Mol. Cell. Biochem., 127/128: 103-113, 1993.
38. Xu, W., Harrison, S. C., and Eck, M. J. Three-dimensional structure of the tyrosine kinase c-scr. Nature (Lond.), 385: 595-602, 1996.
39. Sartor, O., McLellan, C. A., and Chiueh, T. Comparison of scr-family cDNAs reveals distinct mechanisms unlerlying focus formation in transfected fibroblasts. J. Biol. Chem., 267: 21044-21051, 1992.
40. Sartor, O., and Robbins, K. C. Substrate specificity for normal but not mutationally activated variants of src family kinases. J. Biol. Chem., 268: 21014-21020, 1993.